To put it simply, they are extending the run way to have sufficient time to be acquired or get in a partner. My take is that they have proven technology but need time/ dollars to build the data required for fda approval, and they don’t believe they can go alone. Time will tell I suppose.
Brian did say had to offer the rights at a ‘very attractive price’ to the sure we receive sufficient funds to remain viable until we lock in a deal. My take on that is he expects to receive offers more attractive than 1cps. Let’s see!
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
$1.16 |
Change
-0.010(0.86%) |
Mkt cap ! $21.74M | |||
| Open | High | Low | Value | Volume |
| $1.17 | $1.17 | $1.14 | $80.47K | 69.48K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 2150 | $1.16 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.17 | 7380 | 1 |
View Market Depth
| Last trade - 16.10pm 25/07/2025 (20 minute delay) ? |
| OSL (ASX) Chart |